ANNX Share Price | Annexon, Inc. Stock Analysis & Recommendation

Q: What does Annexon, Inc. do?

Overview: Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for classical complement-mediated disorders in the body, brain, and eye, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -54 Million (Quarterly Results - Mar 2025) Market cap: USD 256.73 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.07 Return on Equity: -68.66% Price to Book: 1.05Contact Details: Address: 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA: 94080 Tel: 1 650 8225500 Fax: 1 650 6369773 Website: http://www.annexonbio.com/

Q: Who are in the management team of Annexon, Inc.?

As of March 2022, the management team of Annexon, Inc. includes the following individuals:- Mr. William Young, who serves as the Independent Chairman of the Board.- Mr. Douglas Love, who is the President, Chief Executive Officer, and a Director.- Ms. Jung Choi, who is an Independent Director.- Dr. Emmett Cunningham, who is also an Independent Director.- Dr. Carol Gallagher, another Independent Director.- Mr. Muneer Satter, who is an Independent Director.In summary, the management team consists of a mix of executive leadership and independent directors, with Mr. Douglas Love holding the key executive role as CEO.

Q: Is Annexon, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Annexon, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook, while the weekly MACD and Dow Theory show a mildly bullish sentiment. The Bollinger Bands on a weekly basis are bullish, but the monthly indicators present a mixed picture with bearish signals. In terms of performance, the stock has underperformed significantly against the S&P 500 over the longer term, with a 1-year return of -61.90% compared to the S&P 500's 17.14%, and a 5-year return of -88.27% versus 96.61% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.01 M

Shareholding (Sep 2025)

FII

21.09%

Held by 81 FIIs

DII

39.97%

Held by 46 DIIs

Promoter

5.31%

How big is Annexon, Inc.?

22-Jun-2025

As of Jun 18, Annexon, Inc. has a market capitalization of 256.73 million and reported net sales of 0.00 million with a net profit of -167.38 million over the last four quarters. Shareholder's funds were valued at 293.11 million, and total assets amounted to 350.07 million.

View full answer

What does Annexon, Inc. do?

22-Jun-2025

Annexon, Inc. is a clinical-stage biopharmaceutical company developing therapies for classical complement-mediated disorders, with a market cap of approximately $256.73 million and a recent net profit of -$54 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

View full answer

Who are in the management team of Annexon, Inc.?

22-Jun-2025

As of March 2022, Annexon, Inc.'s management team includes CEO Douglas Love and Independent Chairman William Young, along with several independent directors: Jung Choi, Emmett Cunningham, Carol Gallagher, and Muneer Satter.

View full answer

Is Annexon, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Annexon, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a 1-year return of -61.90% compared to 17.14%.

View full answer

Compare Annexon, Inc. with Similar Stocks

Calidi Biotherapeutics, Inc.Ocean Biomedical, Inc.Gamida Cell Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 828 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.15

Return on Equity

-128.23%

Price to Book

5.13

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-55 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

5.09%

6 Months

84.54%

1 Year

123.75%

2 Years

-21.03%

3 Years

43.58%

4 Years

63.72%

5 Years

-81.71%

Annexon, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-219.38%

EBIT to Interest (avg)

-133.06

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.07

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.13

EV to EBIT

-2.94

EV to EBITDA

-2.99

EV to Capital Employed

-26.24

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-128.23%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 40 Schemes (33.63%)

Foreign Institutions

Held by 81 Foreign Institutions (21.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -57.76% vs -7.08% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-56.10",
          "val2": "-38.60",
          "chgp": "-45.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.90",
          "val2": "-34.80",
          "chgp": "-57.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2.98% vs 5.43% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-150.60",
          "val2": "-140.50",
          "chgp": "-7.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-138.20",
          "val2": "-134.20",
          "chgp": "-2.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-56.10

-38.60

-45.34%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-54.90

-34.80

-57.76%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -57.76% vs -7.08% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-150.60

-140.50

-7.19%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-138.20

-134.20

-2.98%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2.98% vs 5.43% in Dec 2023

All Annual Results

Company CV

About Annexon, Inc.

Annexon, Inc.

Pharmaceuticals & Biotechnology

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Company’s pipeline is based on its platform technology addressing classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its product candidate, ANX005, is a monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its product candidate, ANX007, is an antigen-binding fragment (Fab), formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. It is also developing ANX009, an investigational, subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases.

Company Coordinates

Company Details

180 KIMBALL WAY, SUITE 200 , SOUTH SAN FRANCISCO CA : 94080

Tel: 1 650 8225500

http://www.annexonbio.com/

Registrar Details